TransMedics Group (TMDX) Tops Q4 EPS by 9c; Guides FY23 Reveneus Above Views

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $31.4 million versus the consensus estimate of $24.45 million.

GUIDANCE:

TransMedics Group sees FY2023 revenue of $138-145 million, versus the consensus of $134.71 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Playboy to buy back 16.6M shares from Fortress at $1.05 each
• Worried the AI trade has gone too far? Evercore likes these 4 stocks